These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24490049)

  • 21. Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
    Bosbach B; Deshpande S; Rossi F; Shieh JH; Sommer G; de Stanchina E; Veach DR; Scandura JM; Manova-Todorova K; Moore MA; Antonescu CR; Besmer P
    Proc Natl Acad Sci U S A; 2012 Aug; 109(34):E2276-83. PubMed ID: 22652566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.
    Le Cesne A; Blay JY; Reichardt P; Joensuu H
    Oncologist; 2013; 18(11):1192-9. PubMed ID: 24136010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.
    Van Looy T; Gebreyohannes YK; Wozniak A; Cornillie J; Wellens J; Li H; Vanleeuw U; Floris G; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Sarcoma Res; 2014; 4():10. PubMed ID: 25132955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.
    Guo T; Hajdu M; Agaram NP; Shinoda H; Veach D; Clarkson BD; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
    Clin Cancer Res; 2009 Nov; 15(22):6862-70. PubMed ID: 19861442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Keung EZ; Fairweather M; Raut CP
    Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.
    Gounder MM; Maki RG
    Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1(Suppl 1):S25-43. PubMed ID: 21116624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.
    Tsai HJ; Jiaang WT; Shih NY; Fletcher JA; Lin MJ; Yang MY; Chen CT; Hsu TJ; Wu CC; Lin HY; Chen LT
    Cancer Sci; 2018 Nov; 109(11):3591-3601. PubMed ID: 30142229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
    Ferraro D; Zalcberg J
    Ther Adv Med Oncol; 2014 Sep; 6(5):222-8. PubMed ID: 25342989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 33. Optimal use of targeted agents for advanced gastrointestinal stromal tumours.
    Reichardt P
    Oncology; 2010; 78(2):130-40. PubMed ID: 20389135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation.
    Brohl AS; Demicco EG; Mourtzikos K; Maki RG
    Clin Sarcoma Res; 2015; 5():21. PubMed ID: 26396737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K).
    Spitaleri G; Biffi R; Barberis M; Fumagalli C; Toffalorio F; Catania C; Noberasco C; Lazzari C; de Marinis F; De Pas T
    Onco Targets Ther; 2015; 8():1997-2003. PubMed ID: 26316776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
    Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.